Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge

(2019) Yiwei Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16

(2019) Sima Jeha et al.   JOURNAL OF CLINICAL ONCOLOGY

Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

(2017) Wanda Salzer et al.   LEUKEMIA & LYMPHOMA

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients

(2016) Sebastiaan D.T. Sassen et al.   HAEMATOLOGICA

Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions

(2016) Marc Lavielle et al.   PHARMACEUTICAL RESEARCH

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients

(2016) Sebastiaan D.T. Sassen et al.   HAEMATOLOGICA

Activity and Toxicity of IntravenousErwiniaAsparaginase Following Allergy toE.coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia

(2015) Lynda M. Vrooman et al.   PEDIATRIC BLOOD & CANCER

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group

(2013) W. L. Salzer et al.   BLOOD

L-asparaginase treatment in acute lymphoblastic leukemia

(2010) Rob Pieters et al.   CANCER

Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007

(2010) Dominik Schrey et al.   PEDIATRIC BLOOD & CANCER

Erwiniaasparaginase after allergy toE. coliasparaginase in children with acute lymphoblastic leukemia

(2009) Lynda M. Vrooman et al.   PEDIATRIC BLOOD & CANCER